Euro-Med Laboratories PhilippinesPHS:EURO +1.85%82 PE Ratio without NRI is 10.00 as of Jul. 03, 2026, which is 46% below its 10-year median of 18.60. GuruFocus rates PHS:EURO with a GF Score™ of 82/100 and a GF Value™ of ₱1.02 (Fairly Valued). The stock has 4 warning signs investors should review. Among 654 Drug Manufacturers companies, Euro-Med Laboratories Philippines ranks better than 84.56% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-03), Euro-Med Laboratories Philippines's share price is ₱1.10.
Euro-Med Laboratories Philippines's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₱0.11. Therefore, Euro-Med Laboratories Philippines's PE Ratio without NRI for today is 10.00.
During the past 13 years, Euro-Med Laboratories Philippines's highest PE Ratio without NRI was 88.00. The lowest was 8.00. And the median was 18.60.
Euro-Med Laboratories Philippines (PHS:EURO) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Euro-Med Laboratories Philippines PE Ratio without NRI Related Terms
Euro-Med Laboratories Philippines PE Ratio without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines PE Ratio without NRI Chart
PHS:EURO vs ZTS, UTHR, VTRS: PE Ratio without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's PE Ratio without NRI falls into.
Euro-Med Laboratories Philippines PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Euro-Med Laboratories Philippines's Share Price of today is ₱1.10.
Euro-Med Laboratories Philippines's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₱0.11.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Euro-Med Laboratories Philippines (PHS:EURO) has a PE Ratio without NRI of 10.00 as of Jul. 03, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Euro-Med Laboratories Philippines and its competitors. This is 46% below median its historical median of 18.60. Over the past decade, Euro-Med Laboratories Philippines' PE Ratio without NRI has ranged from 8.00 to 88.00. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #101 out of 654 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Euro-Med Laboratories Philippines' PE Ratio without NRI too high?
Euro-Med Laboratories Philippines' current PE Ratio without NRI of 10.00 is 46% below median its 10-year median of 18.60. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 88.00. The Drug Manufacturers industry median PE Ratio without NRI is 20.87. Euro-Med Laboratories Philippines' value of 10.00 is 52.1% below this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #101 out of 654 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' PE Ratio without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #101 out of 654 companies for PE Ratio without NRI. This places Euro-Med Laboratories Philippines in the top 15% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 20.87. Euro-Med Laboratories Philippines' value of 10.00 is 52.1% below this benchmark. Historically, Euro-Med Laboratories Philippines' own PE Ratio without NRI has ranged from 8.00 to 88.00 over the past decade. While the company's 10-year median is 18.60 vs. the industry median of 20.87, Euro-Med Laboratories Philippines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.87, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current PE Ratio without NRI of 10.00 is 52.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current PE Ratio without NRI is 10.00, which is 46% below median its own 10-year median of 18.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.02, compared to a current price of ₱1.10 — trading 7.8% above its estimated fair value. The current PE Ratio without NRI is 10.00, which is 46% below median its 10-year median of 18.60 and 52.1% below the Drug Manufacturers industry median of 20.87. Euro-Med Laboratories Philippines' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current PE Ratio without NRI is 10.00 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.10 is trading 7.8% above its estimated GF Value™ of ₱1.02.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
PE Ratio without NRI: 10.00 (46% below median its 10-year median of 18.60)
GF Value™: ₱1.02 vs. price of ₱1.10 (7.8% above fair value)
Industry Position: 52.1% below the Drug Manufacturers median (#101 of 654)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Business Description
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
82GF Score
Get the complete analysis for PHS:EURO
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
